» Articles » PMID: 9972970

Giant Cell Arteritis, Polymyalgia Rheumatica, and Viral Hypotheses: a Multicenter, Prospective Case-control Study. Groupe De Recherche Sur L'Artérite à Cellules Géantes

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 1999 Feb 11
PMID 9972970
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Although suspected, a viral etiology has never been proven in giant cell arteritis (GCA). We tested for viruses known to induce multinucleated giant cells in human pathology, which include the parainfluenza viruses (HPIV), respiratory syncytial virus, measles virus, herpesviruses type 1 and 2, and the Epstein-Barr virus.

Methods: A multicenter case-control study on incident cases of temporal arteritis (TA) and polymyalgia rheumatica (PMR). Population based age and sex matched controls were randomly selected. Serological tests for IgG and IgM directed against the viruses listed above were performed, on blood samples taken at the time of clinical diagnosis.

Results: Three hundred five new patients were included over a 5 year period, of whom 159 presented with positive biopsy TA, 70 with negative biopsy TA, and 76 with negative biopsy PMR. Thirty-eight percent of cases versus 20.9% of controls were positive for IgM directed against HPIV (p = 0.00005). The association was stronger in the positive TA subgroup [positivity rate 43.31%; odds ratio with controls 2.89 (95% CI 1.82-4.60, p = 0.000006)] than in the PMR or negative biopsy TA subgroups. Only HPIV type 1 was associated with the disease, regardless of the season or the geographical origin of the cases. Positivity rates for HPIV types 2 and 3 and for the other viruses tested were similar in cases and controls.

Conclusion: Our findings suggest that reinfection with HPIV type 1 is associated with the onset of GCA in a subset of patients, particularly in cases with positive TA biopsy.

Citing Articles

Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis.

Pacoureau L, Barde F, Seror R, Nguyen Y RMD Open. 2023; 9(4).

PMID: 37949615 PMC: 10649904. DOI: 10.1136/rmdopen-2023-003493.


Pathogenesis of giant cell arteritis with focus on cellular populations.

Stamatis P, Turesson C, Michailidou D, Mohammad A Front Med (Lausanne). 2022; 9:1058600.

PMID: 36465919 PMC: 9714577. DOI: 10.3389/fmed.2022.1058600.


An Unusual Side Effect of the COVID-19 Vaccine: A Possible Trigger of Polymyalgia Rheumatica.

Ahmad A, Baker D Cureus. 2022; 14(7):e26617.

PMID: 35949778 PMC: 9356652. DOI: 10.7759/cureus.26617.


Polymyalgia Rheumatica.

Colombo M, Wetzel A, Haumann H, Dally S, Kirtschig G, Joos S Dtsch Arztebl Int. 2022; 119(24):411-417.

PMID: 35635433 PMC: 9533703. DOI: 10.3238/arztebl.m2022.0218.


Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C Drugs Aging. 2019; 36(11):1015-1026.

PMID: 31493201 DOI: 10.1007/s40266-019-00705-5.